國立虎尾科技大學 |

Advances in cancer biomarkers = from biochemistry to clinic for a critical revision /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Advances in cancer biomarkers/ edited by Roberto Scatena.
其他題名:	from biochemistry to clinic for a critical revision /
其他作者:	Scatena, Roberto.
出版者:	Dordrecht :Imprint: Springer, : 2015.,
面頁冊數:	ix, 372 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Pharmacology/Toxicology. -
電子資源:	http://dx.doi.org/10.1007/978-94-017-7215-0
ISBN:	9789401772150

Advances in cancer biomarkers = from biochemistry to clinic for a critical revision /
Advances in cancer biomarkersfrom biochemistry to clinic for a critical revision /[electronic resource] :edited by Roberto Scatena. - Dordrecht :Imprint: Springer,2015. - ix, 372 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.8670065-2598 ;. - Advances in experimental medicine and biology ;780..

Prelims -- I Generality -- II Tumor markers-a critical revision -- Enzymes -- Hormones -- Oncofetal proteins -- Cytokeratins -- Carbohydrate markers -- Blood group antigens -- Genetic markers -- Various protein markers -- III Perspectives -- The role of Circulating tumor Cells as tumor markers -- Index.

At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and "polluted" knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.

ISBN: 9789401772150

Standard No.: 10.1007/978-94-017-7215-0doiSubjects--Topical Terms:

593882
Pharmacology/Toxicology.

LC Class. No.: RC267

Dewey Class. No.: 616.9940072

Advances in cancer biomarkers = from biochemistry to clinic for a critical revision /
LDR:02899nam a2200325 a 4500 001 838079
003 DE-He213
005 20160415092444.0
006 m d
007 cr nn 008maaau
008 160616s2015 ne s 0 eng d
020 $a 9789401772150 $q (electronic bk.)
020 $a 9789401772143 $q (paper)
024 7 $a 10.1007/978-94-017-7215-0 $2 doi
035 $a 978-94-017-7215-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC267
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.9940072 $2 23
090 $a RC267 $b .A244 2015
245 0 0 $a Advances in cancer biomarkers $h [electronic resource] : $b from biochemistry to clinic for a critical revision / $c edited by Roberto Scatena.
260 $a Dordrecht : $c 2015. $b Imprint: Springer, $b Springer Netherlands :
300 $a ix, 372 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.867
505 0 $a Prelims -- I Generality -- II Tumor markers-a critical revision -- Enzymes -- Hormones -- Oncofetal proteins -- Cytokeratins -- Carbohydrate markers -- Blood group antigens -- Genetic markers -- Various protein markers -- III Perspectives -- The role of Circulating tumor Cells as tumor markers -- Index.
520 $a At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and "polluted" knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Oncology. $3 593951
650 2 4 $a Cancer Research. $3 668358
650 1 4 $a Biomedicine. $3 593880
650 0 $a Biochemical markers. $3 582469
650 0 $a Cancer. $3 581034
700 1 $a Scatena, Roberto. $3 888024
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 780. $3 881230
856 4 0 $u http://dx.doi.org/10.1007/978-94-017-7215-0
950 $a Biomedical and Life Sciences (Springer-11642)